High-Flow Nasal Oxygen Noninferior to Noninvasive Ventilation for Acute Respiratory Failure
By Lori Solomon HealthDay Reporter
MONDAY, Dec. 16, 2024 -- High-flow nasal oxygen (HFNO) is noninferior to noninvasive ventilation (NIV) for endotracheal intubation or death within seven days for most patients with acute respiratory failure, according to a study published online Dec. 10 in the Journal of the American Medical Association to coincide with the Critical Care Reviews Down Under meeting, held from Dec. 10 to 11 in Melbourne, Australia.
Israel S. Maia, M.D., Ph.D., from the HCor Research Institute in São Paulo, Brazil, and colleagues assessed whether HFNO is noninferior to NIV on the rates of endotracheal intubation or death at seven days. The researchers randomly assigned 1,766 hospitalized patients with acute respiratory failure (classified into five groups) to HFNO (883 patients) or NIV (883 patients).
The researchers found that the primary outcome of endotracheal intubation or death within seven days occurred in 39 percent in the HFNO group versus 38 percent in the NIV group overall. The primary outcome occurred at the following rates in the immunocompromised patient group with hypoxemia: 57.1 percent in the HFNO group versus 36.4 percent in the NIV group, with enrollment stopped for futility. The corresponding rates were 32.5 versus 33.1 percent in the nonimmunocompromised group with hypoxemia; 10.3 versus 21.3 percent in the acute cardiogenic pulmonary edema group; 51.3 versus 47.0 percent in the hypoxemic COVID-19 group; and 28.6 versus 26.2 percent in the group with chronic obstructive pulmonary disease exacerbation with respiratory acidosis. The incidence of serious adverse events was similar between the groups (HFNO: 9.4 percent; NIV: 9.9 percent).
"The small sample sizes in some patient groups and the sensitivity of the findings to the choice of analysis model suggests the need for further study in patients with chronic obstructive pulmonary disease, immunocompromised patients, and patients with acute cardiogenic pulmonary edema," the authors write.
One author disclosed ties to Roche Diagnostics, Novartis, and Bayer.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Life-Sustaining Treatment Ends Sooner for Uninsured Trauma Patients
FRIDAY, Aug. 2, 2024 -- Early withdrawal of life-sustaining therapy (WLST) is more likely among uninsured trauma patients, according to a study published online July 24...
Preoxygenation With Noninvasive Ventilation Yields Lower Hypoxemia
FRIDAY, June 14, 2024 -- For critically ill adults undergoing tracheal intubation, preoxygenation with noninvasive ventilation results in lower incidence of hypoxemia than...
Hispanic Patients More Likely to Receive Deep Sedation While on Ventilator
TUESDAY, Feb. 27, 2024 -- Hispanic individuals who are hospitalized with respiratory failure have a higher risk for receiving deep sedation while on a ventilator than non-Hispanic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.